Study Shows Superiority of PharmaJet Needle-Free Injector for Poliovirus Vaccine Administration

 PharmaJet, the maker of innovative, needle-free injection technology, announced that a study was published in Heliyon Journal showing PharmaJet needle-free injection is superior to needle and syringe for fractional dose poliovirus vaccine campaigns.(1)

Administration of fractional inactivated poliovirus vaccine (fIPV) using intradermal delivery was previously established as both efficacious and effective in the use of polio vaccine. However, using a needle and syringe for ID delivery can be slow, technically challenging, inconsistent and painful. These factors make it less than ideal for house-to-house campaigns and for mass immunizations. The purpose of this study was to evaluate the feasibility and safety of the Tropis® ID injector for administering fIPV in a campaign setting.

The study demonstrated that it is safe and efficient to use the Tropis device for the administration of fIPV in a campaign setting. Average preparation and administration time was up to 70% faster when compared to needle and syringe, and the needle-free device eliminated vaccine wastage. In fact, Tropis was able to extract an average of 5.3 doses from each 5 dose vial, allowing 32 more children to be vaccinated in the study with the given supply. All vaccinators reported that crying among children was less common, and the device was easy-to-use, with minimal training needed.

"The PharmaJet Tropis simple point and click design is easy-to-use, and ensures consistent and accurate intradermal injection," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc. "Additionally, the significantly faster preparation and administration time compared to traditional ID technique with a needle and syringe, makes it an ideal choice for vaccination campaigns."(1) The PharmaJet Tropis device is currently being used as part of polio eradication efforts in Bangladesh, Cuba, Gambia and Pakistan.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan, August, 2017; Mohammad Tahir Yousafzai et al;

About PharmaJet
PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016.